Graduate School of Information Sciences, Hiroshima City University, 3-4-1 Ozukahigashi, Asaminami-ku, Hiroshima 731-3194, Hiroshima, Japan.
Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Aichi, Japan.
Int J Mol Sci. 2021 Sep 11;22(18):9837. doi: 10.3390/ijms22189837.
Recently, inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) have been proposed as potential therapeutic agents for COVID-19. Studying effects of amino acid mutations in the conformation of drug targets is necessary for anticipating drug resistance. In this study, with the structure of the SARS-CoV-2 Mpro complexed with a non-covalent inhibitor, we performed molecular dynamics (MD) simulations to determine the conformation of the complex when single amino acid residue in the active site is mutated. As a model of amino acid mutation, we constructed mutant proteins with one residue in the active site mutated to alanine. This method is called virtual alanine scan. The results of the MD simulations showed that the conformation and configuration of the ligand was changed for mutants H163A and E166A, although the structure of the whole protein and of the catalytic dyad did not change significantly, suggesting that mutations in His163 and Glu166 may be linked to drug resistance.
最近,严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)主蛋白酶(Mpro)的抑制剂被提议作为 COVID-19 的潜在治疗药物。研究药物靶标构象中氨基酸突变的影响对于预测耐药性是必要的。在这项研究中,我们使用 SARS-CoV-2 Mpro 与非共价抑制剂复合物的结构,进行了分子动力学(MD)模拟,以确定活性位点中单一氨基酸残基突变时复合物的构象。作为氨基酸突变的模型,我们构建了活性位点中一个残基突变为丙氨酸的突变蛋白。这种方法称为虚拟丙氨酸扫描。MD 模拟的结果表明,配体的构象和构型发生了变化,对于突变体 H163A 和 E166A 都是如此,尽管整个蛋白质和催化二联体的结构没有显著变化,这表明 His163 和 Glu166 的突变可能与耐药性有关。